{"id":"NCT01532869","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis","officialTitle":"A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2014-01","completion":"2015-08","firstPosted":"2012-02-15","resultsPosted":"2015-11-05","lastUpdate":"2016-09-23"},"enrollment":87,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Sclerosis, Systemic"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]},{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Tocilizumab","type":"EXPERIMENTAL"}],"summary":"This multicenter, randomized, double-blind, placebo-controlled, two-arm, parallel-group study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in participants with systemic sclerosis. Participants will be randomized to receive either RoActemra/Actemra 162 mg subcutaneously weekly or placebo for 48 weeks. From Week 48 to Week 96, all participants will receive open-label RoActemra/Actemra 162 mg subcutaneously weekly. Anticipated time on study treatment is 96 weeks.","primaryOutcome":{"measure":"Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Placebo","deltaMin":-1.22,"sd":null},{"arm":"Tocilizumab","deltaMin":-3.92,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0915"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":50,"countries":["United States","Canada","France","Germany","United Kingdom"]},"refs":{"pmids":["33294861","29858547","29853453","29066464","27156934"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":44},"commonTop":["Pruritus","Skin ulcer","Arthralgia","Diarrhoea","Gastrooesophageal reflux disease"]}}